Humoral and T Cell Response to SARS‐CoV‐2 Vaccination in Patients With Rheumatoid Arthritis
Authors' conclusion
In this RA cohort vaccinated with homologous and heterologous regimens against COVID-19, 2 out of 10 patients did not develop anti-SARS-CoV-2 IgG, 70% presented with neutralizing activity, and 65% presented with specific T cell response. The use of BBIBP-CorV was associated with deficient humoral and cellular response, whereas treatment with ABA and RTX resulted in an impaired anti-SARS-CoV-2 IgG formation and neutralizing activity.
Study context
- Population
- Patients with rheumatoid arthritis (RA) ≥18 years vaccinated for SARS-CoV-2 per the Argentine National Health Ministry's strategy (homologous and heterologous regimens)
- Participants
- 120 patients
- Outcome
- SARS-CoV-2-specific humoral (anti-SARS-CoV-2 immunoglobulin G (IgG), neutralizing activity) and T cell response (IFN-γ ELISpot) after a two-dose regimen
- Follow-up
- After the second dose
Methodological detailsVaccines mostly homologous: Gam-COVID-Vac 27.5%, ChAdOx1 24.2%, BBIBP-CorV 22.5%; most frequent combination Gam-COVID-Vac/mRNA-1273 21.7%
- Vaccines mostly homologous: Gam-COVID-Vac 27.5%, ChAdOx1 24.2%, BBIBP-CorV 22.5%; most frequent combination Gam-COVID-Vac/mRNA-1273 21.7%
Main finding
As reported in the abstract
Anti-SARS-CoV-2 antibodies
81.7%
Neutralizing activity
70.0%
Specific T cell response
65.3%
Observational data: associations, not effects.
Further findings
Factors associated with response after two doses
- BBIBP-CorV and treatment with abatacept (ABA) and rituximab (RTX) associated with undetectable antibodies and no neutralizing activity
- BBIBP-CorV also associated with absence of T cell response
Safety
Adverse events, total incidence
- Total incidence (events per 1,000 doses)
- 357.1
- BBIBP-CorV, significantly lower (events per 1,000 doses), P < 0.02
- 166.7
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →